Meet Iris! On the clock, she?contributes to the?development of?our target discovery pipeline for growth and sustainability. Off the clock, she’s traveling, hiking, shell fishing and more. Get to know more in this #EmployeeSpotlight. #WeAreWave #ReimaginePossible #WomensHistoryMonth
Wave Life Sciences
生物技术研究
Cambridge，Massachusetts 20,771 位关注者
Unlocking the broad potential of RNA medicines to transform human health
关于我们
We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM?, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing our broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
- 网站
-
https://www.wavelifesciences.com
Wave Life Sciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2012
- 领域
- Biotechnology、Oligonucleotides、Genetic medicines、RNA editing和RNAi
地点
Wave Life Sciences员工
动态
-
As we strive to develop impactful therapies for individuals facing life-changing conditions such as #HuntingtonDisease, we remain dedicated to consistently engaging with and learning from the community. Jamie joined us at Wave this week to share her #HD journey, including her path to joining the Help 4 HD team as a social worker and her ongoing efforts to educate and raise awareness about the needs of the HD community. Jamie’s story, perspective and insights reminded our team of the importance of advocating for others and?for?yourself. #LetsTalkAboutHD
-
-
Our team helped Alpha-1 Foundation celebrate their 30th anniversary at the annual Celtic Connection?this past weekend!?It was an inspiring and beautiful night dedicated to raising awareness?and showing support?for #Alpha1! #AATD #Alpha1Community
-
-
We’re proud to have three Wave team members presenting at #OPTBoston this week! Join Pachamuthu Kandasamy on Tuesday and Chandra Vargeese and Ian Harding on Wednesday to learn more about our best-in-class oligonucleotide chemistry and how we’re opening up new hepatic and extrahepatic therapeutic applications using #RNAediting.?
-
-
What a great week at #CHDI! Our team had productive conversations with #HuntingtonsDisease?researchers and advocates, and?presented on our SELECT-HD results and how we are using biomarkers like caudate atrophy to rapidly advance WVE-003 for HD. View our CHDI posters here:?https://lnkd.in/eaRrUJV2
-
-
Today is?#WorldObesityDay?and we are?proud to serve as corporate sponsors for this unified day of action focused on creating healthier futures for people living with obesity. Check out our WVE-007 team?making the?"?" for obesity?to show our support! #WOD2025
-
-
Today we announced our 4Q & full year 2024 results and provided a business update, including the latest on our clinical trials for WVE-007 in #obesity and WVE-006 in #AATD, as well as expected milestones across our pipeline for 2025. Learn more: https://lnkd.in/eJYG385q
-
-
Tomorrow, March 4, we will present our 4Q and full year 2024 financial results and provide a business update. Register and watch the webcast here: https://lnkd.in/eWx9penC
-
-
Every day we strive to serve as a trusted partner and advocate to the #RareDisease community, determined to put patients and their families’ interests first. In celebration of #RareDiseaseDay we reflect on why we care about rare and what motivates us to unlock the full potential of #RNAmedicines.?
-
Marina Freytsis, PhD has been part of the Wave?Alliance Management and Business Development?team for 5 years. She works closely with our academic and pharma partners?to?help?identify and build new collaboration opportunities that align with our corporate objectives?and that advance scientific understanding of RNA medicines. Learn more about?Marina?in today’s #EmployeeSpotlight. #WeAreWave?#ReimaginePossible
-